AU2023268579A1 - Combination of allosteric and orthosteric egfr inhibitors for the treatment of cancer - Google Patents

Combination of allosteric and orthosteric egfr inhibitors for the treatment of cancer Download PDF

Info

Publication number
AU2023268579A1
AU2023268579A1 AU2023268579A AU2023268579A AU2023268579A1 AU 2023268579 A1 AU2023268579 A1 AU 2023268579A1 AU 2023268579 A AU2023268579 A AU 2023268579A AU 2023268579 A AU2023268579 A AU 2023268579A AU 2023268579 A1 AU2023268579 A1 AU 2023268579A1
Authority
AU
Australia
Prior art keywords
methyl
combination according
indazol
combination
egfr inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023268579A
Other languages
English (en)
Inventor
Georg Jaeschke
Bruno Martoglio
Yvonne Alice Nagel
Christa Ulrike OBST-SANDER
Antonio Ricci
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of AU2023268579A1 publication Critical patent/AU2023268579A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2023268579A 2022-05-13 2023-05-11 Combination of allosteric and orthosteric egfr inhibitors for the treatment of cancer Pending AU2023268579A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP22173211 2022-05-13
EP22173211.8 2022-05-13
EP22175302 2022-05-25
EP22175302.3 2022-05-25
PCT/EP2023/062530 WO2023217924A1 (en) 2022-05-13 2023-05-11 Combination of allosteric and orthosteric egfr inhibitors for the treatment of cancer

Publications (1)

Publication Number Publication Date
AU2023268579A1 true AU2023268579A1 (en) 2024-09-19

Family

ID=86558741

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023268579A Pending AU2023268579A1 (en) 2022-05-13 2023-05-11 Combination of allosteric and orthosteric egfr inhibitors for the treatment of cancer

Country Status (9)

Country Link
US (1) US20260007678A1 (cg-RX-API-DMAC7.html)
EP (1) EP4522113A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025516543A (cg-RX-API-DMAC7.html)
KR (1) KR20250009977A (cg-RX-API-DMAC7.html)
CN (1) CN119173253A (cg-RX-API-DMAC7.html)
AU (1) AU2023268579A1 (cg-RX-API-DMAC7.html)
CA (1) CA3255503A1 (cg-RX-API-DMAC7.html)
TW (1) TW202408534A (cg-RX-API-DMAC7.html)
WO (1) WO2023217924A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2961187T3 (es) 2019-06-21 2024-03-08 Hoffmann La Roche Inhibidor de EGFR para el tratamiento del cáncer
CN116507328A (zh) 2020-12-01 2023-07-28 豪夫迈·罗氏有限公司 新的吲唑衍生物
IL303064A (en) 2020-12-01 2023-07-01 Hoffmann La Roche NEW INDAZOLE ACETYLENE DERIVATIVES

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2961187T3 (es) * 2019-06-21 2024-03-08 Hoffmann La Roche Inhibidor de EGFR para el tratamiento del cáncer
CN116507328A (zh) * 2020-12-01 2023-07-28 豪夫迈·罗氏有限公司 新的吲唑衍生物
IL303064A (en) * 2020-12-01 2023-07-01 Hoffmann La Roche NEW INDAZOLE ACETYLENE DERIVATIVES
JP7798887B2 (ja) * 2020-12-01 2026-01-14 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 新規インダゾール誘導体

Also Published As

Publication number Publication date
CA3255503A1 (en) 2023-11-16
US20260007678A1 (en) 2026-01-08
KR20250009977A (ko) 2025-01-20
CN119173253A (zh) 2024-12-20
EP4522113A1 (en) 2025-03-19
JP2025516543A (ja) 2025-05-30
TW202408534A (zh) 2024-03-01
WO2023217924A1 (en) 2023-11-16

Similar Documents

Publication Publication Date Title
EP3986897B1 (en) Egfr inhibitor for the treatment of cancer
KR102587544B1 (ko) 축합 고리 화합물
EP3986566B1 (en) New egfr inhibitors
US20250042919A1 (en) Tetracyclic oxazepine compounds and uses thereof
US20260007678A1 (en) Combination of allosteric and orthosteric egfr inhibitors for the treatment of cancer
EP4076665B1 (en) Egfr inhibitors
WO2022117487A1 (en) New indazole derivatives
AU2021393722A1 (en) New indazole acetylene derivatives
TW202342461A (zh) 雜環化合物及使用方法
HK40115468A (en) Combination of allosteric and orthosteric egfr inhibitors for the treatment of cancer
RU2853003C1 (ru) Новые индазолацетиленовые производные
HK40071776A (en) Egfr inhibitors